cefprozil: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	CEFPROZIL	cefprozil	FOR SUSPENSION;ORAL	065381	ANDA	NorthStar Rx LLC	16714-396-02	75 mL in 1 BOTTLE (16714-396-02)	2007-01-30
Aurobindo Pharma	CEFPROZIL	cefprozil	FOR SUSPENSION;ORAL	065381	ANDA	NorthStar Rx LLC	16714-396-03	100 mL in 1 BOTTLE (16714-396-03)	2007-01-30
Aurobindo Pharma	CEFPROZIL	cefprozil	FOR SUSPENSION;ORAL	065381	ANDA	NorthStar Rx LLC	16714-397-01	50 mL in 1 BOTTLE (16714-397-01)	2007-01-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supplier landscape for Cefprozil, a second-generation cephalosporin antibiotic. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key intermediate suppliers, identifying current market dynamics, potential vulnerabilities, and strategic considerations for procurement and R&D.

WHO ARE THE PRIMARY API MANUFACTURERS FOR CEFPROZIL?

The production of Cefprozil API is concentrated among a limited number of global manufacturers, primarily located in China and India. These entities possess the necessary regulatory approvals, manufacturing capacity, and technical expertise to produce Cefprozil API that meets stringent quality standards.

Key API manufacturers identified include:

Aurobindo Pharma Limited (India): A major player in the global generic pharmaceutical market, Aurobindo has significant API manufacturing capabilities.
Lupin Limited (India): Another prominent Indian pharmaceutical company with a broad API portfolio and established manufacturing sites.
Takeda Pharmaceutical Company (Japan): While a global pharmaceutical giant, Takeda is involved in the Cefprozil supply chain through its manufacturing and distribution networks, historically having had a role in its initial development and ongoing supply.
Several Chinese Manufacturers: A significant portion of global Cefprozil API production originates from China. Specific company names are often subject to proprietary agreements, but contract manufacturing organizations (CMOs) and dedicated API producers in provinces like Zhejiang and Jiangsu are key contributors. These include entities like Zhejiang NHU Company Ltd. and Jiangsu Yewon Chemical Co., Ltd., which are known for their broad antibiotic API production.

The market is characterized by high barriers to entry due to complex synthesis processes, substantial capital investment for Good Manufacturing Practice (GMP) compliant facilities, and the need for extensive regulatory documentation (e.g., Drug Master Files – DMFs).

WHAT ARE THE KEY INTERMEDIATES REQUIRED FOR CEFPROZIL SYNTHESIS?

The synthesis of Cefprozil involves several critical chemical intermediates. Disruptions in the supply of these intermediates can significantly impact API production timelines and costs. The primary synthetic route typically involves the condensation of a protected 7-aminocephalosporanic acid (7-ACA) derivative with a specific side chain.

Key intermediates include:

7-ACA (7-aminocephalosporanic acid): This is a core building block for many cephalosporin antibiotics. Its production is a complex fermentation and chemical modification process. Suppliers of 7-ACA are often large-scale fermentation and chemical manufacturers.
The Cefprozil Side Chain Precursor: This typically involves derivatives of (R)-2-amino-2-(p-hydroxyphenyl)acetic acid or related activated forms, which are then coupled to the 7-ACA nucleus. The synthesis of this chiral side chain requires specific stereochemical control.
Protecting Groups and Reagents: Various protecting groups and coupling reagents are utilized throughout the synthetic pathway to ensure regioselectivity and chemoselectivity. Examples include silyl ethers for hydroxyl group protection and carbodiimides for amide bond formation.

The geographical concentration of intermediate suppliers, particularly for key raw materials and advanced intermediates, can present supply chain risks. China is a major global supplier for many chemical intermediates used in pharmaceutical synthesis.

HOW ARE CEFPROZIL API SUPPLIERS REGULATED?

Cefprozil API manufacturers are subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national regulatory bodies in other major markets. Compliance with current Good Manufacturing Practices (cGMP) is mandatory.

Key regulatory requirements include:

Drug Master Files (DMFs): Manufacturers must submit comprehensive DMFs to regulatory agencies. These documents detail the manufacturing process, quality control procedures, specifications, and stability data for the API.
Facility Inspections: Manufacturing sites are subject to regular inspections by regulatory authorities to ensure ongoing compliance with cGMP.
Quality Management Systems (QMS): Robust QMS are essential, encompassing all aspects of production, from raw material sourcing to finished API release. This includes detailed batch records, deviation management, and change control.
Impurity Profiling: Manufacturers must thoroughly characterize and control impurities within defined limits, as specified in pharmacopoeias (e.g., USP, EP) and by regulatory guidelines (e.g., ICH Q3A/B).

The regulatory status of a supplier, including a history of successful inspections and a complete, up-to-date DMF, is a critical factor in supplier qualification.

WHAT ARE THE CURRENT MARKET DYNAMICS AND SUPPLY CHAIN RISKS FOR CEFPROZIL?

The Cefprozil API market is largely driven by demand for generic finished dosage forms. The market is competitive, with pricing influenced by manufacturing costs, raw material availability, and regulatory compliance.

Key market dynamics and risks include:

Geographic Concentration of Manufacturing: Reliance on a few key geographical regions (primarily China and India) for API and intermediate production creates vulnerability to geopolitical events, trade disputes, or regional environmental regulations that could disrupt supply.
Raw Material Price Volatility: Fluctuations in the cost of key starting materials, particularly those derived from fermentation (like 7-ACA precursors), can impact API pricing.
Regulatory Scrutiny and Compliance Challenges: Increased global regulatory enforcement means that any lapse in cGMP compliance by a supplier can lead to production halts, product recalls, and significant reputational damage, impacting downstream drug availability.
Logistics and Transportation: Global supply chains are susceptible to disruptions from shipping delays, port congestion, and rising freight costs, which can affect lead times and landed costs of API.
Intellectual Property Landscape: While Cefprozil is an established drug with expired primary patents, secondary patents related to specific polymorphic forms, manufacturing processes, or formulations can still influence market entry and supply.

Companies sourcing Cefprozil API must implement robust supply chain risk management strategies, including multi-sourcing, diligent supplier audits, and contingency planning.

WHAT ARE THE STRATEGIC CONSIDERATIONS FOR CEFPROZIL PROCUREMENT?

Procurement of Cefprozil API requires a strategic approach to ensure reliable supply, cost-effectiveness, and compliance.

Strategic considerations include:

Supplier Qualification and Auditing: Beyond initial regulatory approval, conduct thorough on-site audits to assess a supplier's QMS, operational capabilities, and long-term stability.
Dual Sourcing Strategies: Where feasible, establish relationships with at least two qualified API manufacturers in different geographic regions to mitigate single-source risk.
Contractual Agreements: Develop clear, comprehensive supply agreements that outline quality specifications, delivery schedules, pricing mechanisms, force majeure clauses, and change control procedures.
Inventory Management: Maintain appropriate safety stock levels of API and critical intermediates to buffer against unexpected supply disruptions.
Forward-Looking Market Intelligence: Continuously monitor regulatory changes, raw material market trends, and competitor activities that could impact Cefprozil supply.
Geopolitical Risk Assessment: Evaluate the political and economic stability of countries where key suppliers are located.

Engaging with suppliers early in the R&D or commercialization process allows for better integration of supply chain considerations into product development timelines and market access strategies.

KEY TAKEAWAYS

Cefprozil API manufacturing is concentrated among a limited number of global suppliers, primarily in India and China.
Key intermediates, including 7-ACA and specific side chain precursors, are critical to the supply chain.
Stringent regulatory compliance (cGMP, DMFs) is a mandatory requirement for API manufacturers.
Supply chain risks include geographic concentration, raw material price volatility, and geopolitical factors.
Strategic procurement necessitates dual sourcing, robust supplier qualification, and proactive risk management.

FREQUENTLY ASKED QUESTIONS

Are there any single-source dependencies for critical raw materials in Cefprozil synthesis? The synthesis of Cefprozil relies on several key intermediates, with 7-ACA being a notable example. While multiple suppliers for 7-ACA exist globally, the production is complex and often concentrated among a few large-scale manufacturers, creating potential single-source risks for specific precursor chemicals.
What is the typical lead time for Cefprozil API orders from major manufacturers? Typical lead times for Cefprozil API orders can range from 8 to 16 weeks, depending on the supplier's current production schedule, order volume, and the availability of raw materials. Urgent orders may incur premium pricing and require expedited logistics.
How do impurities in Cefprozil API affect its regulatory approval? Impurities in Cefprozil API must be identified, quantified, and controlled within limits specified by pharmacopoeias (e.g., USP, EP) and ICH guidelines. Failure to meet these specifications can lead to rejection of DMFs, refusal of market authorization, or product recalls.
What impact does environmental regulation in China have on Cefprozil API supply? Increased environmental enforcement in China has led to temporary shutdowns or capacity reductions for chemical manufacturers. This can create significant supply disruptions and price volatility for APIs and intermediates produced in the region, including components for Cefprozil.
How can a pharmaceutical company assess the long-term viability of a Cefprozil API supplier? Long-term viability assessment involves evaluating a supplier's financial health, investment in R&D and facility upgrades, track record of regulatory compliance and quality, and their capacity to adapt to market changes and technological advancements. Ongoing performance monitoring through regular audits and quality reviews is crucial.

CITATIONS

[1] Aurobindo Pharma Limited. (n.d.). API Portfolio. Retrieved from https://www.aurobindo.com/apis/api-portfolio

[2] Lupin Limited. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from https://www.lupin.com/business/api-manufacturing/

[3] Takeda Pharmaceutical Company Limited. (n.d.). Our Business. Retrieved from https://www.takeda.com/company/global-operations/

[4] Zhejiang NHU Company Ltd. (n.d.). API & Intermediates. Retrieved from https://www.zhenghuachem.com/products/api-intermediates/

[5] Jiangsu Yewon Chemical Co., Ltd. (n.d.). Product Catalog. Retrieved from https://www.yewonchem.com/products (Note: Specific product catalog access may vary)

[6] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files-dmfs

[7] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from https://www.ema.europa.eu/en/human-regulatory/overview/active-substances-apis

[8] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines

Suppliers and packagers for generic pharmaceutical drug: cefprozil

cefprozil

CEFPROZIL SUPPLIER LANDSCAPE